The term granulocytosis refers to an abnormal increase in the number of granulocytes in the blood. It is often confused with agranulocytosis, which corresponds to the opposite situation: a severe drop in these same cells. This confusion, fueled by the similarity of the two words, muddles the understanding of patients seeking information. Distinguishing between these two hematological anomalies helps to better identify the risks, symptoms, and treatment options associated with each.
Granulocytosis and agranulocytosis: two blood anomalies not to be confused
Granulocytes are a group of white blood cells that includes neutrophils, eosinophils, and basophils. Their main role is to defend the body against bacterial and fungal infections.
Related reading : Why Choose Handmade Creations to Enhance Your Home and Gifts
Granulocytosis corresponds to an excess of granulocytes in the bloodstream. It most often occurs in response to an active infection, chronic inflammation, intense physiological stress, or certain bone marrow diseases. In contrast, agranulocytosis indicates a near-total disappearance of neutrophils, which severely weakens the immune system.
The clinical consequences of these two states are radically different. Moderate granulocytosis often goes unnoticed and is discovered through a routine blood test. Agranulocytosis, on the other hand, constitutes a medical emergency: the risk of infection becomes significant as soon as the neutrophil count drops below a critical threshold. You can learn everything about granulocytosis according to Pharmanco to deepen the distinction between these two situations.
Further reading : Tips and Delicious Recipes to Enhance Your Everyday Cooking
Symptoms of granulocytosis: what a blood test reveals
Granulocytosis itself does not cause specific symptoms. It is the underlying causes that generate clinical manifestations. A patient with a high granulocyte count may feel perfectly healthy or be suffering from a severe fever.
Signals related to the increase in neutrophils
When granulocytosis accompanies an infection, the usual symptoms dominate: fever, fatigue, localized pain. The doctor then prescribes a blood test that highlights the elevated neutrophil count in the blood.
In the context of chronic inflammatory diseases or certain myeloproliferative syndromes, granulocytosis may persist for several weeks. The diagnosis relies on repeated blood count analysis and the search for a specific cause.
When the excess of granulocytes becomes concerning
A persistent granulocytosis without an identifiable infectious cause requires a thorough evaluation. The doctor then seeks to rule out a bone marrow pathology, such as chronic myeloid leukemia or another myeloproliferative syndrome. Referral to a hematologist becomes necessary as soon as the blood test results deviate from expected values over several successive checks.
Drug and toxic causes: an underestimated angle
While granulocytosis generally results from a normal physiological response, certain iatrogenic situations deserve special attention. The administration of corticosteroids, for example, frequently causes a transient increase in circulating neutrophils. This well-documented phenomenon does not indicate an infection but a direct pharmacological effect on the release of granulocytes from the bone marrow.
Granulocyte growth factors (such as filgrastim or pegfilgrastim) are intentionally used to stimulate neutrophil production in patients with severe neutropenia, particularly after cancer chemotherapy. In this context, the resulting granulocytosis is expected and monitored.
In contrast, some medications can cause the opposite effect, agranulocytosis, through a toxic or immuno-allergic mechanism. Risk profiles vary according to therapeutic classes:
- Synthetic antithyroid drugs are among the most frequently involved molecules in drug-induced agranulocytosis
- Some antipsychotics, including clozapine, require regular hematological monitoring with scheduled blood tests
- Non-steroidal anti-inflammatory drugs and certain antibiotics can, more rarely, trigger a sudden drop in neutrophils
Immediate discontinuation of the suspected medication remains the first therapeutic measure in the case of confirmed agranulocytosis. Recovery of neutrophils generally takes one to two weeks after the offending product is removed.
Treatment and management according to the type of granulocyte imbalance
Treatment entirely depends on the identified cause. Reactive granulocytosis related to a bacterial infection normalizes with the resolution of the infection, most often under appropriate antibiotic therapy. No specific treatment targets granulocytosis itself in this case.
Management of granulocytosis related to a myeloproliferative syndrome
When the excess of granulocytes is part of a hematological disease, treatment falls under specialized hematology. Accurate diagnosis involves a myelogram, a bone marrow biopsy, and cytogenetic analyses. The therapeutic plan is tailored to the underlying pathology, whether it is chronic myeloid leukemia or another syndrome.
Emergency of febrile agranulocytosis
The combination of fever and severe neutropenia constitutes a hospital emergency. Management relies on:
- Rapid hospitalization, often in a protected room to limit the risk of infection
- Administration of broad-spectrum intravenous antibiotics, started even before the results of microbiological samples
- Possible use of granulocyte growth factors to accelerate the recovery of neutrophils
- Close monitoring of the blood count until a satisfactory neutrophil count is recovered
The prognosis of drug-induced agranulocytosis remains favorable when the diagnosis is made quickly and the responsible medication is identified without delay. Available data do not always allow for predicting which patient will develop this complication, justifying vigilance during any known-risk treatment.
The distinction between granulocytosis and agranulocytosis leads to very different care pathways. A high granulocyte count calls for a methodical etiological assessment, while a collapse of neutrophils requires a response within hours. In both cases, the blood test remains the first-line examination, and communication with the treating physician or hematologist determines the quality of care.